



INDIAN PHARMACOPOEIA COMMISSION
(MINISTRY OF HEALTH & FAMILY WELFARE, GOVERNMENT OF INDIA)
National Coordination Centre- Pharmacovigilance Programme of India (PvPI)

SECTOR-23, RAJ NAGAR, GHAZIABAD- 201 002.
Tel No: 0120- 2783392, 2783400, 2783401
e-mails: pvpi@ipcindia.net lab.ipc@gov.in, Web: www.ipc.gov.in

File No- P.14019/01/2019-20

Date: 28/03/2020

Advisory for Reporting Adverse Events/Adverse Drug Reactions due to use of Hydroxychloroquine as prophylaxis for SARS-CoV-2 infection (COVID-19)

As per Recommendation of empiric use of Hydroxychloroquine for prophylaxis of SARS-CoV-2 infection uploaded on the website of Ministry of Health and Family Welfare, Government of India (<https://www.mohfw.gov.in/>)

One of the key considerations is that:

The Prophylactic use of Hydroxy-chloroquine to be coupled with the Pharmacovigilance for the adverse drug reactions through the self reporting using the Pharmacovigilance Programme of India (PvPI) Helpline/App.

As the nation, is facing a huge challenge to fight against the COVID-19 from spreading across the communities, therefore during the prophylactic use of hydroxychloroquine if any adverse event is encountered by the patients, such adverse events may be reported by the Patients themselves or by the Health Care Professionals on the following

PvPI Helpline No.1800 180 3024

Timing : 9.00 AM to 5.30 PM (Monday to Friday)

Such Adverse Events may also be reported through the Mobile App

“**ADR PvPI**” which is freely available from Google Play Store.

In addition to above options, the Adverse Events/Adverse Drug Reaction may be reported to nearest Adverse Drug Reaction Monitoring Centers (AMCs), the list of AMCs is available on the website of Indian Pharmacopoeia Commission on the following web link -

http://www.ipc.gov.in/images/LIST_OF_270_AMC_UNDER_PvPI.pdf

This is for kind information of all concerned.

Sd/-
(Dr. Jai Prakash)
Secretary-cum-Scientific Director (I/C)
Officer-in-Charge, PvPI